Bal Pharma
79.40
+1.55(+1.99%)
Market Cap₹126.41 Cr
PE Ratio19.60
IndustryHealthcare
Company Performance:
1D+1.99%
1M-9.56%
6M+9.61%
1Y-20.54%
5Y-19.14%
View Company Insightsright
More news about Bal Pharma
11Feb 26
Bal Pharma Q3FY26 Results: Net Profit Surges 181.84% YoY to ₹194.62 Lakhs
Bal Pharma Limited delivered outstanding Q3FY26 results with net profit jumping 181.84% year-on-year to ₹194.62 lakhs, while revenue from operations grew 20.03% to ₹8,749.48 lakhs. The company's Board of Directors approved the unaudited financial results during their meeting on February 11, 2026, with statutory auditors SSJNB & Co providing an unmodified opinion, demonstrating strong operational efficiency and regulatory compliance.
 no imag found
08Jan 26
Bal Pharma Issues Postal Ballot Notice for Independent Director Appointment
Bal Pharma Limited has initiated a postal ballot process for shareholder approval of Dr. Mukesh Beekamchand's appointment as Independent Director for a five-year term. The e-voting period runs from January 9-February 7, 2026, with results expected by February 10. This follows the company's Q2 financial results showing revenue of ₹7,374.95 lakhs and net profit of ₹78.17 lakhs.
 no imag found
07Nov 25
Bal Pharma Defers Subsidiary Merger Decision, Citing Need for More Data
Bal Pharma Limited has postponed its decision on the proposed merger of its subsidiary, Lifezen Healthcare Pvt Ltd, with the parent company. The Board of Directors found the available data inadequate for making an informed decision during their recent meeting. The management has been instructed to re-present the proposal with all necessary details. The board meeting was held on 11.08.2025, and the company provided clarification to the stock exchange on 06.11.2025 regarding the deferred decision.
 no imag found
11Aug 25
Bal Pharma Reports Q1 FY2026 Results, Approves Employee Stock Option Plan
Bal Pharma Limited released its Q1 FY2026 financial results. Standalone revenue from operations was ₹6563.51 lakhs with a net profit of ₹32.31 lakhs. Consolidated revenue stood at ₹6587.09 lakhs with a net profit of ₹20.85 lakhs. The company announced its 38th AGM for September 25, 2025, to be held virtually. Book closure dates are set from September 19 to 25, 2025. The Board approved an Employee Stock Option Plan-2025, subject to shareholder approval. Auditors provided an unmodified opinion on the financial results. The company continues to operate in the 'Pharmaceuticals' segment.
 no imag found
29Jul 25
Bal Pharma Schedules Board Meeting to Discuss Q1 Results, ESOP, and Subsidiary Merger
Bal Pharma has scheduled a Board of Directors meeting for August 11, 2025, with a comprehensive agenda. Key items include reviewing Q1 financial results, planning the 38th AGM, considering an Employee Stock Option Plan-2025, and potentially merging subsidiary Lifezen Healthcare Pvt Ltd. A trading window closure is in effect from June 1 to August 14, 2025, for designated persons and employees.
 no imag found
Bal Pharma
79.40
+1.55
(+1.99%)
1 Year Returns:-20.54%
Industry Peers
Sun Pharmaceutical
1,935.50
(-0.17%)
Divis Laboratories
6,836.00
(+0.34%)
Torrent Pharmaceuticals
4,901.50
(+0.07%)
Cipla
1,439.40
(-0.13%)
Zydus Life Science
1,150.80
(-0.71%)
Lupin
2,496.30
(-0.28%)
Mankind Pharma
2,525.10
(-0.27%)
Dr Reddys Laboratories
1,244.30
(-1.36%)
Aurobindo Pharma
1,564.70
(-1.43%)
Laurus Labs
1,537.80
(+2.02%)